Medicine and Dentistry
Diffuse Large B-Cell Lymphoma
100%
International Prognostic Index
71%
Overall Survival
53%
Immigrant
50%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
31%
Cohort Analysis
28%
Acute Myeloid Leukemia
25%
Malignant Neoplasm
25%
CHOP
25%
Hematological Cancer
25%
Beta 2 Microglobulin
25%
Elderly Patient
25%
Follicular Lymphoma
25%
Vincristine
25%
Chemotherapy-Induced Peripheral Neuropathy
25%
Lenalidomide
25%
Bortezomib
25%
Clinical Trial
18%
Rituximab
18%
Clinician
8%
High Risk Population
6%
Randomized Controlled Trial
6%
Electrocorticography
6%
Kidney Function
6%
Arm
6%
Medicine
6%
Low Risk Population
5%
Cancer Therapy
5%
Adverse Event
5%
Keyphrases
Diffuse Large B-cell Lymphoma (DLBCL)
50%
International Prognostic Index
40%
Lymphoma Patients
31%
Lymphoma
30%
Trial Eligibility
25%
Prognostic Score
25%
Data-driven Analysis
25%
Prognostic Marker
25%
β2-microglobulin (β2-MG)
25%
Clinical Nomogram
25%
Population-based Study
25%
Migrant Patients
25%
Non-Western Immigrants
25%
Danish Population
25%
National Comprehensive Cancer Network
21%
Overall Survival
21%
Orphan Drug Designation
14%
Restricted Mean Survival
12%
Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
12%
Immigration Status
10%
Clinical Trials
7%
Low Risk
7%
Impact of Immigration
7%
Low Socioeconomic Status
7%
C-index
6%
ECOG Performance Score
6%
Low-risk Group
5%
Newly Diagnosed
5%
Low-risk Patients
5%
Clinical Prognostic Model
5%
5-year Survival
5%
B-cell Lymphoma 2 (Bcl-2)
5%
Number of Hospitalization
5%
Pharmacology, Toxicology and Pharmaceutical Science
Diffuse Large B Cell Lymphoma
75%
Overall Survival
73%
Malignant Neoplasm
55%
Beta 2 Microglobulin
25%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
25%
Lenalidomide
25%
Bortezomib
25%
Chemotherapy-Induced Peripheral Neuropathy
25%
Vincristine
25%
Rituximab
19%
Orphan Drug
9%
Cohort Study
8%
Survival Rate
8%
Adverse Event
5%
